GSK Bio
NEWS
Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look.
Another recall has been issued for ranitidine tablets due to the presence of a carcinogen contaminant.
GlaxoSmithKline announced results from its pivotal DREAMM-2 Phase III trial of belantamab mafodotin in multiple myeloma.
Pharma and biotech companies strengthen their leadership teams and boards with this week’s hires.
Submission follows completion of a Clinical Endpoint study
Hertfordshire Local Enterprise Partnership is to invest £1.2m into Stevenage Bioscience Catalyst (SBC) to help grow a world-class cell and gene therapy cluster.
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
HES is a rare group of inflammatory disorders that affects approximately 20,000 people around the world.
Merck plunked down $576 million to acquire San Diego-based Calporta to gain access to preclinical TRPML1 agonists that are seen as potential treatments for neurodegenerative disorders such as Alzheimer’s or Parkinson’s.
JOBS
IN THE PRESS